Our Mission

To work with management and investors to create and support superior companies. To work as a Director on the Board being held to the highest standards of ethics and expertise.

Our Philosophy

Science Futures believes that it will always be important to invest in new ideas and cutting edge science. The biotechnology revolution that started in the late 70's captivated the minds of investors as well as scientists. The creation of robust new biological based pharmaceutical and medical device companies has been supported by the work of Science Futures.

We have invested in genius science ideas that had competent management at the top. Science Futures teams have written new business plans that have received funding from top tier venture capital funds. Science Futures supports entrepreneurs to realize their dreams of building important and disruptive product companies.
Science Futures supported new financing vehicles which included venture capital, partnerships and Initial Public Offerings and follow on financings. Keep the science moving is our philosophy.

Our Investment Strategy

Science Futures has invested in biotechnology and medical companies as an angel investor, as a limited partner and by creating and running fund-of-funds. In 1998, the first such fund-of-funds Science Futures LLC, was invested in TVM-Capital's Medical Ventures Fund. In 2000, Science Futures invested in TVM-Capital V fund as a venture partner. Science Futures LLC II invested in NanoStream, Inc. and Wafergen, Inc. In 2008, Science Futures LLC Vietnam Fund was formed to invest in life sciences and healthcare investments in Vietnam.

Nola Masterson, Founder

Nola Masterson works with BoardWise clients on governance practices and coaches directors and aspirational directors. She is an experienced global executive and board leader serving on public company, venture-backed private company and non- profit organization boards. Her successful business experience, as CEO and co- founder of Sequenom, (SQNM) and the first analyst in biotechnology on Wall Street with Drexel Burnham Lambert and Merrill Lynch, followed successful business building at Millipore for eight years. She has experience in managing her own venture fund, as well as being a Venture Partner in a major European IT and life sciences venture fund, TVM Capital. During her 10 years on the Repros Therapeutics (RPRX) Board she has advised the CEO on strategy, finance, operations, and recruitment of the board. Areas of expertise include medical device, pharmaceuticals, scientific tools, separation processes and diagnostics technology as well as genetic analysis.

One strength she brings is her understanding, at several levels, of the “DNA” that makes a great company. Her leadership style is as a synthesizer, to create a professional Board environment that is aligned with, and which contributes to the success of, companies at every stage in their development.

Ms. Masterson has been certified by the American College of Corporate Directors for 2014 as a Certified Professional Director, and is listed in the Intrabond Capital Registry of Corporate Directors. She has solid experience in board position recruitment and transition processes, in building productive board cultures and aligning these with CEOs and senior executive accountabilities.

Ms. Masterson started her own venture fund in 1998.As a venture investor, she served on the Board of EpiCept Corporation, which was focused on vascular disruptive agents, while it was a private company, and on the Board of Nanostream, Inc., a venture backed company focused on assay detection, liquid chromatography, and sample preparation. She served on the Board of Omicia, Inc, and a genomics translation company for 7 years. Her experience as CEO of Sequenom helped her understand NGS, and the software needed to support its translation to medicine.

She currently is the Managing Director of Science Futures Management Company and works as an advisor, board member and investor. She is Chair of the Board of Repros Therapeutics and serves as Chair of the Compensation Committee of the company and sits on the Audit Committee. She also serves on the Board of Resonance-med in Chicago; Zivo Biosciences, a public company headquartered in Detroit MI. She also has served on the Board of Generex Biotechnology Corporation, a Toronto, Canada-based publically traded (NASDAQ: GNBT) company focused on the development of drug delivery systems and antigen technologies, and served on the Audit, and Compensation Committee and Chaired the Nomination And Governance Committee of the Generex Board. She is a special advisor to several private companies and is Chair Emeritus of California Life Science Institute, a best-practices and workforce development arm of the Northern California life sciences industry association. Currently she is an Adjunct Professor at University of San Francisco in the School of Business Management, teaching the Business of Biotech. She lectures and writes for the Life Science Foundation.

Ms. Masterson also serves as Chair on the Silicon Valley Chapter Board of the American Diabetes Association, and is co-Chair of the San Francisco chapter of WomenCorporateDirectors.



SCIENCE FUTURES INVESTS IN THE BUSINESS OF LIFE